Robert Califf’s likely confirmation by the Senate would send him to the Food and Drug Administration commissioner post with him “mindful” that modernizing the agency’s Rx-to-OTC switch paradigm has been a regulatory goal for a decade.
Califf, who previously was commissioner for 11 months ending in January 2017, answered Health, Education, Labor and Pensions Committee members...